### Drug Therapy Protocols:
**Packed Red Blood Cells – Group O negative**

<table>
<thead>
<tr>
<th>Policy code</th>
<th>DTP_PABC_0119</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>January, 2019</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to packed red blood cells – group O negative administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless stated otherwise.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>January, 2022</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: [Clinical.Guidelines@ambulance.qld.gov.au](mailto:Clinical.Guidelines@ambulance.qld.gov.au)

### Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


---

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en](http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en)

For copyright permissions beyond the scope of this license please contact: [Clinical.Guidelines@ambulance.qld.gov.au](mailto:Clinical.Guidelines@ambulance.qld.gov.au)
**Drug class**
Haemoglobin replacement

**Pharmacology**
Packed red blood cells (PRBC) replace lost haemoglobin, aiming to improve oxygen carrying capacity of the blood and volume replacement.[1,2]

**Metabolism**
N/A

---

**Indications**
- Ongoing haemodynamic instability secondary to haemorrhage (following an appropriate volume resuscitation strategy)

**Contraindications**
- Non-consenting conscious patient (e.g. Jehovah Witness)

**Precautions**
- Previous transfusion reaction
- Immunosuppressed patients
- Hyperkalaemia

**Side effects**
- Acute haemolytic transfusion reaction
- Acute febrile transfusion reaction
- Anaphylaxis/allergic reactions
- Infection (bacterial, viral including low risk for HIV, Hep C and other blood borne viruses)
- Fluid overload
- Acute lung reaction
- Electrolyte imbalances
- Hypothermia
- Acidosis

**Presentation**
- 200–400 mL bag, Group O negative PRBC

**Onset (INF) | Duration (INF) | Half-life**
---|---|---
Immediate | Variable | N/A
Packed Red Blood Cells – Group O negative

Schedule
- Unscheduled.

Routes of administration

- Intravenous infusion (IV INF)
- Intraosseous infusion (IO INF)

Special notes
- Ambulance offers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consult and Advice Line.
- Each unit contains enough haemoglobin to raise the haemoglobin concentration in an average size adult by approximately 10 g/L.
- PRBC should be mixed thoroughly by gentle inversion before use and then transfused through an intravenous line approved for blood administration incorporating a standard 170 – 200 micrometre filter.
- Patients receiving transfusions shall be monitored for signs of potential complications of transfusions and any suspected problems must be dealt with swiftly and efficiently. Severe reactions are most likely to occur within the first 15 minutes of the transfusion. If any reaction occurs cease infusion immediately and discuss with RSQ coordinator or QAS Clinical Consultation and Advice Line (as appropriate). Clinical presentation of transfusion reactions include: tachycardia, hypertension, fever, rigors, headache, myalgia, altered level of consciousness, bronchospasm, pulmonary oedema, and worsening coagulopathy.[1]

Special notes (cont.)
- Vital signs (temperature, pulse, respirations and blood pressure) shall be measured and recorded at the beginning and during each transfusion, least every 15 minutes.
- The bag label numbers of all PRBC transfusions administered to the patient must be documented on the e-ARF.
- All transfusion reactions must be immediately reported to the QAS on-call medical officer.
- All used PRBC infusion bags are to be left with the medical/nursing staff at the receiving hospital.
- Informed consent for transfusion means a dialogue has occurred between the patient and the clinician. The significant risks, benefits and alternatives to transfusion, including the patient’s right to refuse the transfusion, will have been discussed. As a result of the discussion the patient should:
  - understand what medical action is recommended
  - be aware of the risks and benefits associated with the transfusion
  - appreciate the risks, and possible consequences of not receiving the recommended therapy
  - be given an opportunity to ask questions
  - give consent for the transfusion.
# Adult dosages

## Ongoing haemodynamic instability secondary to haemorrhage (following an appropriate volume resuscitation strategy)

|   | IV INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
PRN – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |
|---|---|---|
|   | IO INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
PRN – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |

# Paediatric dosages

## Ongoing haemodynamic instability secondary to haemorrhage (following an appropriate volume resuscitation strategy)

|   | IV INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
PRN – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |
|---|---|---|
|   | IO INF | CCP ESoP aeromedical – RSQ consultation and approval required in all situations.  
CCP ESoP HARU – QAS Clinical Consultation and Advice Line approval required in all situations.  
PRN – titrate according to the indication and patient’s physiological response to treatment. Administer via a QAS approved blood warmer (Belmont® buddy lite™/enFlow®). |